Royalty buyer builds Hong Kong hub as mainland biotech out-licensing hits record highs
What a new Hong Kong base signals about royalty financing becoming a go-to funding lane for Chinese drug developers.
By Mohammed Al-Shehri·· 3 min
Loading the Newsroom
Curating from trusted global sources…